Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136123 | 0.87 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL22750861 | 0.87 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2552451 | 0.84 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31186989 | 0.84 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710653 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800228 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL566228 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16629728 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800550 | 0.83 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034147-B2 | Nucleoside analog libraries | IRM LLC (BM) | 2006-04-25 | — | — | US | disclosed |
| US-20040006176-A1 | Nucleoside analog libraries | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-01-08 | — | — | US | disclosed |
| US-20030225205-A1 | Nucleoside analog libraries | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2003-12-04 | — | — | US | disclosed |
| WO-2003045966-A2 | NUCLEOSIDE ANALOG LIBRARIES | IRM LLC (BM) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225205-A1 | Nucleoside analog libraries | ENTPD5, NT5C2, SAMHD1 | SLC28A1 20/4885SLC28A2 23/4885SLC29A1 16/4885 |
| US-20040006176-A1 | Nucleoside analog libraries | ENTPD5, NT5C2, SAMHD1 | SLC28A1 20/4885SLC28A2 23/4885SLC29A1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.